top of page

EraCal Therapeutics Ltd.

The biotech-company EraCal Therapeutics Ltd. is a spin-off from the University of Zurich and Harvard University. The company is privately held by a biotech-specialized investor base.

Board of Directors


A. Kessler Ph.D.


Ann Kessler held various senior research positions at Roche for over 26 years. She launched the obesity research program, led its clinical development, and brought orlistat (Alli, Xenical) to the market.


B. Ernst Ph.D.

Board Member

Bettina Ernst is a biotech entrepreneur and investor. She serves the Swiss Biotech community in various roles thanks to her deep experience in medical research in the US and Europe.

Scientific Advisory Board

Foto Henning B SAB.jpg

H. Böttcher Ph.D.

Henning Böttcher is the former head of medicinal chemistry at Merck KGaA.


Prof. F. Engert

Florian Engert is a neuroscience expert and tenured professor at Harvard University.

Meyer Druck.jpg

G. Meyer Ph.D.

Gerd Meyer is Head of Plexus Ventures CH, a leading global development & licensing firm.


Prof. T. A. Lutz

Thomas A. Lutz is an obesity and diabetes expert and tenured professor at the University of Zurich.

12_01_T_Weller_0010 - Copy.jpg

T. Weller Ph.D.

Thomas Weller is the former head of medicinal chemistry at Idorsia/Actelion.



S. Breitler Ph.D.

Chief Operational Officer

Simon Breitler holds a Ph.D. in synthetic organic chemistry from ETH Zurich which was complemented with a fellowship at Harvard University. He previously led a team in preclinical chemistry, manufacturing, and control (CMC) department at Roche.


J. Jordi Ph.D.

Josua Jordi is a biochemist ETH by training and completed a Ph.D. in physiology at the University of Zurich. He developed EraCal’s platform as a postdoctoral fellow at Harvard University.

bottom of page